Children’s Hospital Los Angeles – Acute myeloid leukemia

Submitted By:
Published Date:
January 25, 2020

Access Program Information

The purpose of this study is to provide expanded access to ASP2215 for a single subject with
refractory FLT3-mutated AML without access to comparable or alternative therapy.

Rare Disease:
Acute myeloid leukemia